Latest Breaking News On - உயிர் மருத்துவ மையம் - Page 1 : comparemela.com

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine. The SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a threat to global public health and has now caused more than 3.92 million deaths worldwide. The study analyzed data from a phase 2/3 vaccine efficacy trial conducted across 19 sites in the UK. The team from the University of Oxford, NIHR Oxford Biomedical Centre, AstraZeneca PLC, Public Health England in Salisbury and the Oxford COVID Vaccine Trial Group say the analysis aimed to facilitate the development and licensure of future vaccines in situations where large vaccine efficacy trials are not feasible.

United kingdomMashonaland eastAstrazeneca chadoxMerryn voyseySally robertsonOxford biomedical centreUniversity of oxfordVaccine trial groupPublic health englandWorld health organizationBiomedical centreTrial groupWorld healthஒன்றுபட்டது கிஂக்டம்மஷோனலண்ட் கிழக்குசாலி ராபர்ட்சன்